Comparative Advertising Heats Up As Heartburn OTCs Jockey For Position
This article was originally published in The Tan Sheet
Executive Summary
The Rx-to-OTC switch of Procter & Gamble's Prilosec OTC proton pump inhibitor appears to have spawned a growing trend of comparative advertisements for OTC heartburn drugs
You may also be interested in...
Prilosec OTC Continues To Gain Share Amid Advertising, Supply Pressures
Procter & Gamble says sales of Prilosec OTC will face difficult year-over-year comparisons in the current quarter, indicating that growth for the heartburn drug may be slowing
Prilosec OTC Continues To Gain Share Amid Advertising, Supply Pressures
Procter & Gamble says sales of Prilosec OTC will face difficult year-over-year comparisons in the current quarter, indicating that growth for the heartburn drug may be slowing
Prilosec OTC Continues To Gain Share Amid Advertising, Supply Pressures
Procter & Gamble says sales of Prilosec OTC will face difficult year-over-year comparisons in the current quarter, indicating that growth for the heartburn drug may be slowing